[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368591-105":59,"doc-detail-368591-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","validation-of-an-ai-enabled-exometranscriptome-liquid-biopsy-platform-early-detection-mrd-disease-monitoring-and-therapy-selection","Validation of an AI-enabled exome/transcriptome liquid biopsy platform - early detection, MRD, disease monitoring, and therapy selection","","Cancer management depends on accurate diagnosis, precise therapy selection, and highly sensitive monitoring of disease burden. Caris Assure is a multifunctional blood-based assay that couples whole exome and whole transcriptome sequencing on plasma and leukocytes with advanced machine learning. CLIA validation used 1,910 samples, engineering models from 376,197 tissue profiles and 7,061 matched blood-tissue pairs. MCED performance reached high sensitivities across stages I–IV at 99.6% specificity, while MRD and recurrence monitoring showed significant outcome separation, supporting unified liquid biopsy use for early detection and precision therapy selection.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/validation-of-an-ai-enabled-exometranscriptome-liquid-biopsy-platform-early-detection-mrd-disease-monitoring-and-therapy-selection/368591/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/validation-of-an-ai-enabled-exometranscriptome-liquid-biopsy-platform-early-detection-mrd-disease-monitoring-and-therapy-selection/368591.png","ImageObject",300,407,{"name":92,"@type":93},"Melati","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-09","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"How does the platform support MRD and recurrence monitoring?","Question",{"text":112,"@type":113},"A dedicated MRD & Monitoring model was trained on 3,439 patients and validated on independent sets for MRD and monitoring. Patients predicted to have an event showed significantly shorter disease-free survival than those predicted not to have an event, using a tumor naïve approach.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},368591,1790215687,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":131,"language":132,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":67,"update_tm":136,"read_time":36,"preview_page_count":19,"preview_urls":137},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nValidation of an AI-enabled exome/ transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors  \nJ. Abraham1,10, V. Domenyuk1,10, N. Perdigones1, S. Klimov1, S. Antani1, T. Yoshino2,  \nE. I. Heath3, E. Lou4, S. V. Liu5, J. L. Marshall5, W. S. El-Deiry6, A. F. Shields3, M. F. Dietrich7,  \nY. Nakamura2, T. Fujisawa2, G. D. Demetri8, A. Barker9, J. Xiu1, D. A. Sacchetti1, S. Stahl1,  \nR. Hahn-Lowry1, A. Stark1, J. Swensen1, G. Poste9, D. D. Halbert1, M. Oberley1, M. Radovich1,  \nG. W. Sledge1 & David B. Spetzler1􀀍  \nEffective clinical management of patients with cancer requires highly accurate diagnosis, precise therapy selection, and highly sensitive monitoring of disease burden. Caris Assure is a multifunctional blood-based assay that couples whole exome and whole transcriptome sequencing on plasma and leukocytes with advanced machine learning techniques to satisfy all three clinical testing needs on one platform. Caris Assure for therapy selection was CLIA validated using 1,910 samples. 376,197 tissue profiles along with 7,061 paired blood and tissue profiles were used to engineer features for three machine learning models. The MCED model was trained on 1,013 patients and validated on an independent set of 2,675 patients. The tissue of origin for MCED model was trained on 1,166 samples and validated using 5-fold cross validation. The MRD & Monitoring model was trained on 3,439 patients and validated on two independent sets of 86 patients for MRD and 101 patients for monitoring. For early detection, sensitivities for stages I-IV cancers (n = 284, 129, 90, 23 respectively) were 83.1%, 86.0%, 84.4%, and 95.7%, all at 99.6% specificity (n = 2149). The diagnostic first-line procedure for tissue of origin was determined for 8 categories with a top-3 accuracy of 85% for stage I and II cancers. Detection of driver mutations for therapy selection from blood collected within 30 days of matched tumor tissue, demonstrated high concordance (PPA of 93.8%, PPV of 96.8%) using CHIP subtraction. For MRD and recurrence monitoring, the disease-free survival of patients whose cancers were predicted to have an event was significantly shorter than those predicted not to have an event using a tumor naïve approach (HR = 33.4, p \u003C 0.005, HR= 4.39, p = 0.008, respectively). The data presented here demonstrate a unified liquid biopsy platform that uses blood-based whole-exome and transcriptome sequencing coupled with artificial intelligence to address the important clinical needs in multi-cancer early detection, monitoring of MRD and recurrent cancers, and precision selection of molecularly targeted therapies.  \nKeywords MCED, Liquid biopsy, Whole exome, Whole transcriptome, MRD, AI  \nNext Generation Sequencing (NGS) technology applied to nucleic acids is now routinely utilized across the continuum of cancer care to measure SNV/INDEL, microsatellite instability status (MSI), tumor mutational burden (TMB), copy number, expression, and fusions1,2. Current guidelines recommend concurrent testing of  \n1Caris Life Sciences, 350 W. Washington St, Irving, TX 85281, USA. 2National Cancer Center Hospital East, Chiba, Japan. 3Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA. 4University of Minnesota, Minneapolis, MN, USA. 5Lombardi Comprehensive Cancer Center, Washington, D. C., DC, United States. 6Brown University, Providence, RI, USA. 7Oncology Network, Orlando, FL, US. 8Dana-Farber Cancer Institute and Ludwig Center, Harvard Medical School, Boston, MA, United States. 9Arizona State University, Phoenix, AZ, USA. 10These authors jointly supervised this work: J. Abraham and V. Domenyuk. 􀀍 email: [dspetzler@carisls.com](dspetzler@carisls.com)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nboth tissue and blood in multiple tumor types3,4. For late-stage disease, NGS of both lim","cbCaibF8qNDrOHaM","https://ap.wps.com/l/cbCaibF8qNDrOHaM","pdf",3311958,16,"English","# Study validation and platform purpose\n## Assay workflow (WES/WTS + machine learning)\n## CLIA validation and training datasets\n## Early detection performance (MCED)\n## Tissue-of-origin classification and accuracy\n## Therapy-selection mutation concordance\n## MRD and recurrence monitoring outcomes\n# Clinical implications and model unification","[{\"question\":\"How does the platform support MRD and recurrence monitoring?\",\"answer\":\"A dedicated MRD \\u0026 Monitoring model was trained on 3,439 patients and validated on independent sets for MRD and monitoring. Patients predicted to have an event showed significantly shorter disease-free survival than those predicted not to have an event, using a tumor naïve approach.\"}]","Validation of an AI-enabled exome/transcriptome liquid biopsy platform - early detection, MRD, disease monitoring, and therapy selection | PDF",1790177622,[138,142,146,150],{"page_no":8,"url":139,"width":140,"height":141},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cad244956c7052ea62589c43ca351197.webp",983,1291,{"page_no":14,"url":143,"width":144,"height":145},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5f451e8149bf926b286afec6444318b.webp",982,1290,{"page_no":81,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4e66f9b8eeecef46b74a1dd3d434cbf.webp",981,1289,{"page_no":19,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df95d01858991e986fbbe43665114884.webp",980,1287]